Nova Publishers
My Account Nova Publishers Shopping Cart
HomeBooksSeriesJournalsReference CollectionseBooksInformationSalesImprintsFor Authors
            
  Top » Catalog » Journals » World Heart Journal » Volume 9 Issue 1 Articles » My Account  |  Cart Contents  |  Checkout   
Quick Find
  
Use keywords to find the product you are looking for.
Advanced Search
What's New? more
Theory of Literature
$243.00
Shopping Cart more
0 items
Information
Shipping & Returns
Privacy Notice
Conditions of Use
Contact Us
Bestsellers
01.Attenuation of Acute Systemic Inflammatory Response after Valve Surgery (pp. 45-50)
Notifications more
NotificationsNotify me of updates to Attenuation of Acute Systemic Inflammatory Response after Valve Surgery (pp. 45-50)
Tell A Friend
 
Tell someone you know about this product.
Attenuation of Acute Systemic Inflammatory Response after Valve Surgery (pp. 45-50) $50.00
Authors:  Najah R. Hadi, Fadhil G. Al-Amran, Alaa Abdul-Hussein Naeem, Ali F. Abdalsaheb, Mohammed A. Alturfy ,Waleed Khalid Fakher, and Yaser Qays Majeed
Abstract:
Background: Montelukast is a selective cysteinyl-leukotriene1 (CysLT1) receptor antagonist. In recent years, several investigations have shown that montelukast possesses both secondary anti-inflammatory activities and antioxidant effects. Hence this study aimed to determine the possible protective effect of montelukast in myocardial ischemia reperfusion injury induced by cardiopulmonary bypass during valve replacement surgery.

Patients and methods: A total of 60 patients with valvular disease undergoing elective valve surgery were enrolled in a randomized, single-blind clinical trial. These patients were subdivided into two main groups: Group 1 (montelukast-treated group) consisted of 30 patients who underwent valve surgery; they were given montelukast sodium (10 mg tab) at bedtime for 3 days before surgery. Group 2 (control group) consisted of 30 patients who underwent valve surgery without taking montelukast.
For each group, blood samples were collected at the following times: T0, after anesthesia; T1, before aortic cross clamp; T2, after aortic cross clamp; and T3, 24 hours after surgery. The inflammatory biomarkers TNF-, IL-6, 2 macroglobulin/Creatinine ratio, CTnI and ALT were determined. For each group, an echo study was undertaken to determine the ejection fraction (EF) before surgery and three months after surgery.

Results: Concentrations of TNF-, IL-6, 2 macroglobulin / Creatinine ratio, CTnI, and ALT were significantly higher (P < 0.05) in the control group than in the montelukast-treated group at different sampling times. There was
no significant difference in EF between the two
groups before surgery, but EF was significantly higher
(p < 0.05) in the montelukast-treated group than in the control group after surgery.

Conclusion: Montelukast treatment is beneficial to patients who normally undergo a cardiopulmonary bypass during valve replacement surgery. 


Available Options:
Version:
Special Focus Titles
01.Violent Communication and Bullying in Early Childhood Education
02.Cultural Considerations in Intervention with Women and Children Exposed to Intimate Partner Violence
03.Chronic Disease and Disability: The Pediatric Lung
04.Fruit and Vegetable Consumption and Health: New Research
05.Fire and the Sword: Understanding the Impact and Challenge of Organized Islamism. Volume 2

Nova Science Publishers
© Copyright 2004 - 2022

Attenuation of Acute Systemic Inflammatory Response after Valve Surgery (pp. 45-50)